Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1019-29.
View in:
PubMed
subject areas
Aged
Aged
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Non-Small-Cell Lung
Carcinoma, Non-Small-Cell Lung
Chemotherapy, Adjuvant
Chemotherapy, Adjuvant
Deoxycytidine
Deoxycytidine
Drug Administration Schedule
Drug Administration Schedule
Drug Synergism
Drug Synergism
Humans
Humans
Infusions, Intravenous
Infusions, Intravenous
Lung Neoplasms
Lung Neoplasms
Male
Male
Maximum Tolerated Dose
Maximum Tolerated Dose
Middle Aged
Middle Aged
Neoplasm Staging
Neoplasm Staging
Nomograms
Nomograms
Radiotherapy, Adjuvant
Radiotherapy, Adjuvant
Suramin
Suramin
Taxoids
Taxoids
Treatment Outcome
Treatment Outcome